Laparoscopic Gastrojejunostomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Laparoscopic gastrojejunostomy (LGJ) is a minimally invasive surgical procedure that creates a new anastomosis (connection) between the posterior wall of the stomach and a loop of proximal jejunum, bypassing the gastric outlet and duodenum to allow food and gastric contents to drain directly from the stomach into the small intestine. It is performed through 4–5 small port incisions (typically 5–12 mm) using laparoscopic instrumentation and a circular or linear stapler to create the anastomosis. The procedure does not remove the obstructed segment of duodenum or pancreatic head; it bypasses it functionally, allowing the patient to eat and drink despite obstruction. LGJ is a palliative procedure for unresectable malignant gastric outlet obstruction — most commonly from locally advanced or metastatic pancreatic head or periampullary cancer — and a definitive treatment for benign obstruction from peptic ulcer disease, with a Heineke-Mikulicz pyloroplasty performed simultaneously if the pylorus itself is the site of dysfunction. The laparoscopic approach produces significantly less surgical trauma than open gastrojejunostomy, reducing recovery time and allowing earlier resumption of oral intake — critical in palliative oncological patients with limited functional reserve and short life expectancy. An endoscopic alternative — duodenal self-expanding metal stenting — provides faster but shorter-term relief in patients unsuitable for surgery.

Gastrojejunostomy is indicated for patients with gastric outlet obstruction (GOO) — a syndrome of nausea, vomiting, inability to tolerate solid or liquid food, and progressive weight loss caused by mechanical blockage of the stomach or proximal duodenum. In the malignant context, GOO is most commonly caused by unresectable pancreatic cancer of the head, periampullary carcinoma, gallbladder cancer, or duodenal cancer compressing the duodenum from outside. Approximately 20% of pancreatic cancer patients develop GOO requiring intervention. LGJ is preferred over endoscopic duodenal stenting for patients with an expected survival of more than 3–6 months, adequate performance status (ECOG 0–2) for general anaesthesia, and no major ascites that would preclude laparoscopic surgery. In benign disease, peptic ulcer scarring of the pylorus or proximal duodenum causing chronic obstruction, and post-surgical adhesion-related GOO, are treated definitively with gastrojejunostomy. Prophylactic gastrojejunostomy at the time of biliary bypass (hepaticojejunostomy) for unresectable pancreatic cancer is increasingly performed to pre-empt the 20% risk of subsequent GOO development, reducing the need for a second operation.

Under general anaesthesia with the patient supine, four to five laparoscopic ports are placed in the upper abdomen — a 12 mm camera port at the umbilicus, a 12 mm working port in the right upper quadrant (for the stapler), and 5 mm ports for retraction. The peritoneal cavity is surveyed for extent of disease, adhesions, and ascites. A loop of proximal jejunum approximately 40–60 cm from the duodenal-jejunal flexure (ligament of Treitz) is selected and positioned in contact with the posterior wall of the stomach, tension-free and anti-colic (anterior to the transverse colon). Stay sutures approximate the stomach and jejunum. A side-to-side anastomosis is created using a laparoscopic linear stapler (60 mm) inserted through enterotomies in both the stomach posterior wall and the antimesenteric border of the jejunum, fired to create the anastomotic lumen, and the common enterotomy is closed with a second firing of the stapler or with an intracorporeal suture. The anastomosis is leak-tested by injecting methylene blue or air through a nasogastric tube and the anastomotic diameter is confirmed by passage of a 19 mm circular stapler gauge. The mesenteric defect is closed to prevent internal herniation. Ports are removed and skin closed with absorbable sutures.

Laparoscopic gastrojejunostomy provides durable relief of gastric outlet obstruction in 80–90% of patients, allowing resumption of oral diet and improving quality of life significantly in patients with advanced cancer or severe benign obstruction. The laparoscopic approach offers the key benefits of minimally invasive surgery — 3–5 port incisions of 5–12 mm rather than a large laparotomy wound, significantly less post-operative pain requiring lower opioid requirements, faster return to oral diet (typically day 3–5 versus 5–7 days for open surgery), shorter hospital stay (3–5 days versus 7–10 days), and faster overall recovery. Compared with endoscopic duodenal metal stenting, surgical LGJ provides substantially longer-duration relief: median patency of the surgical bypass exceeds 12 months, compared with a re-obstruction rate of 10–20% at 6 months for metal stents (from tumour in-growth or stent migration). The SUSTAIN randomised trial demonstrated that surgical gastrojejunostomy provided significantly better long-term relief of GOO than endoscopic stenting in patients with advanced periampullary malignancy and anticipated survival over 3 months. For patients with benign peptic ulcer-related obstruction, LGJ with vagotomy is curative and eliminates the need for chronic proton pump inhibitor use. Prophylactic LGJ in unresectable pancreatic cancer prevents future GOO in 80% of at-risk patients with no significant added morbidity.

Anastomotic leak is the most serious specific complication, occurring in 2–5% of gastrojejunostomies and presenting with peritonitis, fever, and sepsis on days 3–7; managed with drainage, antibiotics, nil-by-mouth, and occasionally re-operation. Delayed gastric emptying — the anastomosis creates normal anatomy but peristaltic coordination may be impaired — occurs in 10–20% and is managed conservatively with prokinetics, nutritional support (parenteral or enteral via jejunal feeding tube if prolonged), and patient reassurance that it resolves in most cases within 2–4 weeks. Anastomotic haemorrhage is rare (under 2%) and managed endoscopically or operatively. Wound infection affects 2–5% of laparoscopic cases (versus 10–15% open). Marginal ulceration at the anastomotic margin occurs in 3–5% and requires proton pump inhibitor therapy. Internal hernia through the mesenteric defect, if not closed at surgery, causes acute bowel obstruction and requires emergency surgery. In palliative cases, disease progression often determines the eventual failure of the bypass, with recurrent obstructive symptoms from peritoneal metastases or anastomotic involvement in advanced malignancy. General anaesthesia and pneumoperitoneum carry cardiopulmonary risks particularly in medically debilitated patients with advanced cancer — careful pre-operative assessment by an anaesthetist familiar with the patient's oncological and nutritional status is essential.

Following laparoscopic gastrojejunostomy, a nasogastric tube is maintained for decompression on day 0–1 and removed when gastric drainage reduces below 200 ml per 8 hours. Clear fluids are commenced on day 1–2 and progressed to free fluids and a soft diet over days 3–5 as tolerated. Metoclopramide or domperidone prokinetics are given routinely to stimulate gastric emptying. A Gastrografin meal study may be performed on day 3–4 to confirm anastomotic integrity and emptying before discharge. Hospital stay is typically 3–5 days. Discharge home requires the patient to tolerate a light diet and manage pain with oral analgesics. A proton pump inhibitor (omeprazole 20–40 mg daily) is prescribed for 8–12 weeks to reduce marginal ulcer risk. Return to light activities is possible at 1–2 weeks; lifting above 5 kg is avoided for 4 weeks. Oncological management — chemotherapy, palliative care review, imaging — continues in parallel. Patients are reviewed in clinic at 2–4 weeks to confirm diet progression. Nutritional assessment by a dietitian at every oncological review supports adequate caloric intake during cancer treatment.